Skip to content

Usefulness of Multi-parametric, Quantitative MR Imaging for Staging of Hepatic Fibrosis in the Patients With Chronic Hepatitis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01981421
Enrollment
60
Registered
2013-11-11
Start date
2013-06-30
Completion date
2015-12-31
Last updated
2013-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis

Keywords

Liver fibrosis, Elastography, MR Elastography, Quantitative imaging

Brief summary

Liver fibrosis has been considered as irreversible change. However, recent study showed that early stage liver fibrosis could be reversible and a lot of new drugs are now developing or developed including anti-viral treatment. Liver biopsy is considered as golden standard for the evaluation of liver fibrosis. But biopsy specimen through biopsy only consists of 1/50000 of the whole liver and heterogeneity of liver fibrosis, accurate diagnosis of liver fibrosis is still challenging. Furthermore, its invasive nature, repeated biopsy is practically almost impossible. Hence, non-invasive diagnosis of liver fibrosis is important. In this study we hypothesized that multi-parametric MR imaging including MR elastography, conventional DWI, and IVIM can predict changes of liver stiffness after anti-viral therapy in patients with chronic liver disease. We will enroll 60 biopsy-proven patients and perform multi-parametric MR imaging at the enrollment and one year later to evaluate changes in quantitative values in MR.

Interventions

None listed

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who had chronic hepatitis * Patients who underwent liver biopsy within 6 months * Patients older than 18 years old

Exclusion criteria

* patient who had pregnancy * patient 18 or below 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Changes in quantitative values measured from Multi-parametric MRI before and after anti-viral treatment1 year after enrollmentElasticity, conventional ADC value, IVIM ADC value, T2\* value, T1 rho value will be compared before and after anti-viral treatment

Countries

South Korea

Contacts

Primary ContactMi-Suk Park, MD
radpms@yuhs.ac82-2-2228-7400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026